Business · 19/10/2026

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

Pooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumors Additional analyses highlight first-line clinical outcomes and patient-reported quality of…